Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is unknown. We retrospectively evaluated nivolumab effi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2017-07, Vol.28 (7), p.1532-1539
Hauptverfasser:	Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., Nonagase, Y., Takahama, T., Tanizaki, J., Tanaka, K., Yoshida, T., Tanimura, K., Takeda, M., Yoshioka, H., Ishida, T., Mitsudomi, T., Nishio, K., Nakagawa, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - pathology Disease Progression Disease-Free Survival Drug Resistance, Neoplasm - genetics epidermal growth factor receptor ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics ErbB Receptors - metabolism Female Genetic Predisposition to Disease Humans Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - immunology Lung Neoplasms - pathology Lymphocytes, Tumor-Infiltrating - drug effects Lymphocytes, Tumor-Infiltrating - immunology Male Middle Aged Mutation Nivolumab non-small-cell lung cancer Patient Selection PD-L1 Phenotype Precision Medicine Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Retrospective Studies T790M Time Factors Treatment Outcome Tumor Microenvironment tumor-infiltrating lymphocyte
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!